Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Squamous Non-Small Cell Lung Cancer: early-phase trial registry
5 of 7 indexed Squamous Non-Small Cell Lung Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 5 currently recruiting · #2,497 of 28,707 conditions by registered trial count
Squamous Non-Small Cell Lung Cancer: 7 US clinical trials tracked, 5 recruiting.
Squamous Non-Small Cell Lung Cancer is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Alentis Therapeutics, running 2 of these trials.
Enrollment posture brief
Registry condition squamous-non-small-cell-lung-cancer
OPEN 5 | RECR 71% | LATE 0 | EARLY 6 | RANK #2497 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Advanced Endometrial Carcinoma (71% recruiting · 7 trials)
Squamous Non-Small Cell Lung Cancer lists 5 open slots (71% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Squamous Non-Small Cell Lung Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Squamous Non-Small Cell Lung Cancer is recruiting above its size-band peers.
5 of 7 indexed trials (71.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Squamous Non-Small Cell Lung Cancer research.
Alentis Therapeutics accounts for 2 of 7 trials (28.6%). 6 distinct sponsors appear on at least one study for this condition label.
-
Typical Squamous Non-Small Cell Lung Cancer enrolment sits around 180 participants.
Median target enrolment is 180 among the 7 trials that report a genuine target (sentinel values excluded). 0 of those (0%) plan for fewer than 100 participants.
-
Squamous Non-Small Cell Lung Cancer research is mostly interventional.
6 interventional and 1 observational studies make up this index (85.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
AstraZeneca
NCT05123482
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Volastra Therapeutics
NCT05902988
A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Merck Sharp & Dohme
NCT07221474
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Alentis Therapeutics
NCT07169734
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
Alentis Therapeutics
NCT06747585
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
Arcus Biosciences
NCT04736173
A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung
Boehringer Ingelheim
NCT04552535
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Squamous Non-Small Cell Lung Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Squamous Non-Small Cell Lung Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Squamous Non-Small Cell Lung Cancer page
7 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Squamous Non-Small Cell Lung Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Alentis Therapeutics sponsors the most Squamous Non-Small Cell Lung Cancer trials on record, review their full trial history before evaluating a specific study. See Alentis Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Squamous Non-Small Cell Lung Cancer condition card totals 7 registered trials; most-linked intervention Paclitaxel; top US site state Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.